Prevention of VTE in Nonorthopedic Surgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

被引:1481
作者
Gould, Michael K. [1 ]
Garcia, David A. [2 ]
Wren, Sherry M. [3 ]
Karanicolas, Paul J. [4 ]
Arcelus, Juan I. [5 ]
Heit, John A. [6 ]
Samama, Charles M. [7 ]
机构
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[2] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA
[3] Stanford Sch Med, Stanford, CA USA
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[5] Univ Granada, Sch Med, Granada, Spain
[6] Mayo Clin, Coll Med, Rochester, MN USA
[7] Hotel Dieu Univ Hosp, Dept Anaesthesiol & Intens Care, Paris, France
关键词
D O I
10.1378/chest.11-2297
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: VTE is a common cause of preventable death in surgical patients. Methods: We developed recommendations for thromboprophylaxis in nonorthopedic surgical patients by using systematic methods as described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: We describe several alternatives for stratifying the risk of VTE in general and abdominal-pelvic surgical patients. When the risk for VTE is very low (, 0.5%), we recommend that no specific pharmacologic (Grade 1B) or mechanical (Grade 2C) prophylaxis be used other than early ambulation. For patients at low risk for VTE (similar to 1.5%), we suggest mechanical prophylaxis, preferably with intermittent pneumatic compression (IPC), over no prophylaxis (Grade 2C). For patients at moderate risk for VTE (similar to 3%) who are not at high risk for major bleeding complications, we suggest low-molecular-weight heparin (LMWH) (Grade 2B), low-dose unfractionated heparin (Grade 2B), or mechanical prophylaxis with IPC (Grade 2C) over no prophylaxis. For patients at high risk for VTE (similar to 6%) who are not at high risk for major bleeding complications, we recommend pharmacologic prophylaxis with LMWH (Grade 1B) or low-dose unfractionated heparin (Grade 1B) over no prophylaxis. In these patients, we suggest adding mechanical prophylaxis with elastic stockings or IPC to pharmacologic prophylaxis (Grade 2C). For patients at high risk for VTE undergoing abdominal or pelvic surgery for cancer, we recommend extended-duration, postoperative, pharmacologic prophylaxis (4 weeks) with LMWH over limited-duration prophylaxis (Grade 1B). For patients at moderate to high risk for VTE who are at high risk for major bleeding complications or those in whom the consequences of bleeding are believed to be particularly severe, we suggest use of mechanical prophylaxis, preferably with IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C). For patients in all risk groups, we suggest that an inferior vena cava filter not be used for primary VTE prevention (Grade 2C) and that surveillance with venous compression ultrasonography should not be performed (Grade 2C). We developed similar recommendations for other nonorthopedic surgical populations. Conclusions: Optimal thromboprophylaxis in nonorthopedic surgical patients will consider the risks of VTE and bleeding complications as well as the values and preferences of individual patients.
引用
收藏
页码:E227S / E277S
页数:51
相关论文
共 199 条
[1]   Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].
Agnelli, G ;
Bergqvist, D ;
Cohen, AT ;
Gallus, AS ;
Gent, M .
BRITISH JOURNAL OF SURGERY, 2005, 92 (10) :1212-1220
[2]   A clinical outcome-based prospective study on venous thromboembolism after cancer surgery -: The @RISTOS project [J].
Agnelli, G ;
Bolis, G ;
Capussotti, L ;
Scarpa, RM ;
Tonelli, F ;
Bonizzoni, E ;
Moia, M ;
Parazzini, F ;
Rossi, R ;
Sonaglia, F ;
Valarani, B ;
Bianchini, C ;
Gussoni, G ;
Andreoni, B ;
Biffi, R ;
Cenciarelli, S ;
Capussotti, L ;
Calgaro, M ;
Polastri, R ;
Zorzi, D ;
Mazzini, G ;
Tubaro, A ;
Perna, R ;
Vicentini, C ;
Montemurro, S ;
Caliandro, C ;
Ruggeri, E ;
Gennari, L ;
Brocchi, A ;
Quagliuolo, V ;
Scarpa, RM ;
Ragni, F ;
Conti, G ;
Cretarola, E ;
Pagliarulo, A ;
D'Achille, G ;
Bartoli, A ;
Bussotti, C ;
Ricci, E ;
Servoli, A ;
Carrieri, G ;
Corvasce, T ;
Disabato, G ;
Moretti, R ;
Bencini, L ;
Cantafio, S ;
Scatizzi, M ;
Scambia, G ;
Foti, E ;
Frigerio, L .
ANNALS OF SURGERY, 2006, 243 (01) :89-95
[3]   Extended perioperative thromboprophylaxis in patients with cancer [J].
Akl, Elie A. ;
Terrenato, Irene ;
Barba, Maddalena ;
Sperati, Francesca ;
Muti, Paola ;
Schunemann, Holger J. .
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (06) :1176-1180
[4]   Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival [J].
Alcalay, A ;
Wun, T ;
Khatri, V ;
Chew, HK ;
Harvey, D ;
Zhou, H ;
White, RH .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1112-1118
[5]   Deep vein thrombosis among patients entering cardiac rehabilitation after coronary artery bypass surgery [J].
Ambrosetti, M ;
Salerno, M ;
Zambelli, M ;
Mastropasqua, F ;
Tramarin, R ;
Pedretti, RFE .
CHEST, 2004, 125 (01) :191-196
[6]  
American Society for Metabolic and Bariatric Surgery, 2005, RAT SURG TREATM MORB
[7]   Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways [J].
Andtbacka, RHI ;
Babiera, G ;
Singletary, SE ;
Hunt, KK ;
Meric-Bernstam, F ;
Feig, BW ;
Ames, FC ;
Ross, MI ;
Dejesus, Y ;
Kuerer, HM .
ANNALS OF SURGERY, 2006, 243 (01) :96-101
[8]  
[Anonymous], 1994, BMJ, V308, P235
[9]  
[Anonymous], 2012, CHEST S
[10]  
Azorin JF, 1997, ANN CARDIOL ANGEIOL, V46, P341